Inflammatory Marker sTREM-1 Reflects the Clinical Stage and Respiratory Tract Obstruction in Allergic Asthma Bronchiale Patients and Correlates with Number of Neutrophils
Table 1
Characteristics of investigated asthma bronchiale patients.
Patients
Number
(%)
Age (mean ± STD)
(ANOVA)
Healthy subjects
19
100
37.3 ± 13.7
AB
76
100
37.4 ± 21.4
>0.05
Mild intermittent AB (AB1)
28
36.8
22.0 ± 10.6
Mild persistent AB (AB2)
18
23.7
29.7 ± 15.7
>0.05*
Moderate persistent AB (AB3)
14
18.4
48.1 ± 26.2
<0.001*
Severe persistent AB (AB4)
16
21.1
55.5 ± 9.7
<0.001*
Exacerbated AB
25
32.9
54.7 ± 19.0
Nonexacerbated AB
51
67.1
30.0 ± 18.2
<0.0001**
Respiratory tract obstruction (RTO+)
30
39.5
52.1 ± 19.2
Without RTO (RTO−)
46
60.5
24.7 ± 12.9
<0.001**
Anti-IgE therapy
11
14.5
54.1 ± 13.0
Without anti-IgE therapy
65
85.5
34.6 ± 21.2
<0.001**
AB: asthma bronchiale, *significance between AB2 versus AB1, AB3 versus AB1, AB4 versus AB1, **significance between age of patients in exacerbated versus nonexacerbated asthma, asthma with versus without respiratory tract obstruction, patients with versus without anti-IgE therapy.
